

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 November 2001 (22.11.2001)

PCT

(10) International Publication Number
WO 01/87276 A1

(51) International Patent Classification⁷: A61K 9/70, A61F 13/02, A61L 15/16, A61M 37/00

(74) Agent: HUH, Sang, Hoon; 13th floor, Hyecheon Building, 831 Yeoksam-dong, Gangnam-ku, Seoul 135-792 (KR).

(21) International Application Number: PCT/KR01/00783

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 15 May 2001 (15.05.2001)

(25) Filing Language: English

(26) Publication Language: English

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(30) Priority Data:
2000-26091 16 May 2000 (16.05.2000) KR

(71) Applicant (*for all designated States except US*): SAMYANG CORPORATION [KR/KR]; 263, Yonji-dong, Chongno-ku, Seoul 110-470 (KR).

Published:

— with international search report


For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): KIM, Ho, Chin [KR/KR]; 210-1004 Saemムry Apt., Doosan-2dong, Seo-ku, Daejeon 302-122 (KR). YOON, Hye, Jeong [KR/KR]; 11-16, Pyun-dong, Seo-ku, Daejeon 302-190 (KR).

(54) Title: HYDROGEL COMPOSITION FOR TRANSDERMAL DRUG DELIVERY

WO 01/87276 A1



(57) Abstract: The present invention relates to a hydrogel composition for transdermal drug delivery, more specifically to a hydrogel composition for transdermal drug delivery containing acrylate polymers like acrylic acid polymer, methacrylic acid polymer, alkyl acrylate polymer, alkyl methacrylate polymer or copolymers thereof as compatibilizers which enable both hydrophilic and lipophilic permeation enhancers to be applicable in the hydrogel composition in order to effectively control skin penetration of drugs.

HYDROGEL COMPOSITION FOR TRANSDERMAL DRUG DELIVERY

FIELD OF THE INVENTION

The present invention relates to a hydrogel composition for transdermal drug delivery and more specifically, to a hydrogel composition for transdermal drug delivery comprising a hydrophilic polymer base, a drug, a lipophilic permeation enhancer and a compatibilizer consisting essentially of an acrylate polymer which compatibilizes the lipophilic component, i.e. the enhancer, with the hydrophilic polymer base and which renders a uniform composition which is thermodynamically stable. The acrylate polymers such as acrylic acid polymers, methacrylic acid polymers, alkyl acrylate polymers, alkyl methacrylate polymers or copolymers thereof function as compatibilizers in this invention which enables both the hydrophilic and lipophilic components to be uniformly mixed in a hydrogel composition thereby providing for effective drug delivery.

BACKGROUND OF THE INVENTION

Transdermal drug delivery has many advantages over oral or injection means for administering drugs into the body such as efficiency and easiness of control of drug release and administration. Transdermal delivery of various drugs is well known in the art of drug delivery. However, not all drugs can be applied as a transdermal drug delivery system because most of the drugs cannot effectively penetrate the skin. Therefore, the skin-penetration of drugs has to be increased by altering the physical and chemical properties of the skin keratotic layer or subcutaneous fat layer by decreasing the diffusional resistance through reversible damage or increasing the solubility of the drugs in the skin in order to obtain enough skin-penetration for the drug to be effective. Additives performing these actions can be collectively referred to as permeation enhancers.

Generally, a polymer base is used for the transdermal delivery of drugs, as a solvent for the drugs and the skin permeation enhancers. A polymer base

should have sufficient mechanical strength, elasticity and adhesion to skin to be used as transdermal base. Much research has been undertaken to obtain these physical properties. For example, Okabe discloses a polymer base containing a water-soluble preparation, polyacrylamide gel. A gel including 5 multivalent metal salt in polyacrylic acid or its salt [Japanese Patent Publication No. 3-167117], and gel including monomers having sulfonic acid groups [Japanese Patent Publication No. 4-91021] are also known. However, those water-soluble preparations are easily dissociated and since most of proteins have positive or negative charges at above or below their isoelectric 10 point, there is a problem of the drug being bonded to the dissociated preparation.

Hydrogel patches for transdermal delivery of drugs are also known in the art. These patches typically include an inert, impervious backing layer, an adhesive layer containing a polymer base and the drug, optional selected 15 excipients, and a release liner that is peeled off and discarded before applying the patch to the skin. Suitable polymer bases may be one or more members selected from the group consisting of polyvinyl alcohol and polyvinyl pyrrolidone, maleic anhydride/vinyl ether copolymer, gelatin, alginate, hydroxyethyl methacrylate, cargeenane, hydroxyethyl cellulose, silicone 20 rubber, agar, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, methyl cellulose, carboxyvinyl copolymer, polyethylene oxide, polyethylene glycol, polyacryl amide, polyhydroxyethyl methacrylate, polydioxolane, polyacrylic acid, polyacryl acetate, polyacryl amide and polyvinyl chloride may be used. Preferred are polyvinyl alcohol, polyvinyl pyrrolidone, maleic 25 anhydride/vinyl ether copolymer and hydroxyethyl cellulose. The drug and selected excipients, if any, are directly incorporated into the hydrophilic polymer solution and then mixed to give a hydrogel composition containing the drug and excipients. See, for example, Makoto Haga et al., *Lecture Summary of the 112th Conference of The Pharmaceutical Society of Japan*, 4, 52(1992)], Riviere J. E. et al., *J. Pharm. Sci.*, 81(6), 504(1992), Banga A. K. et al., *Pharm. Res.*, 30 10(5), 697(1993), Japanese Patent Publication No. 3-193057. However, these

gels exhibit poor adhesion to skin.

Japanese Patent Publication No. 5-230313 discloses a gel obtained by mixing highly water-absorptive or hydrophilic polymer with polyvinyl alcohol. Though this gel has sufficient adhesion, it has poor mechanical strength and thus it is difficult to form the gel. There have been attempts to increase the crosslinking density by adding a crosslinking agent, like glutaldehyde, or by irradiation in order to increase the mechanical strength. Although this method improves the mechanical strength to some degree, the water content and adhesiveness of the gel decrease so that it is no longer suitable to be used as transdermal polymer base.

US Patent No. 4,593,053 discloses a hydrophilic gel matrix comprising a polar plasticizer and a hydrophilic gel matrix of polyvinyl pyrrolidone and polyvinyl alcohol. US Patent No. 5,082,663 discloses a water-soluble polymer gel of carboxymethyl cellulose including moisturizers like glycerol, sorbitol, propylene glycol and 1,3-butanediol. However, since these polymer gel matrices are water-soluble or hydrophilic, the permeation enhancers and the drugs used are limited to those that are water-soluble or hydrophilic. Since the skin layer like the keratotic layer or the subcutaneous fat, which functions as the greatest penetration barrier for most of drugs, is lipophilic or sub-lipophilic, it is well known that a sufficient penetration rate cannot be obtained with hydrophilic or water-soluble permeation enhancer only. In addition, most of conventional hydrogel compositions suffer the drawback of being unstable with respect to the water and humectant included therein. In other words, these preparations tend to synerese, i.e. to exclude the liquid, water component of the gel.

Accordingly, a technique of preparing an uniform, stable, hydrogel composition for transdermal drug delivery, which includes both a hydrophilic component, i.e. a hydrophilic polymer base, and lipophilic substances, i.e. permeation enhancers, is needed.

The present invention provides a stable hydrophilic polymer preparation which includes both hydrophilic and lipophilic substances as permeation enhancers in order to effectively deliver drugs transdermally. Briefly, in one aspect, the invention relates to an improved transdermal drug delivery composition comprising a hydrophilic polymer base, a drug, a lipophilic permeation enhancer and a compatibilizer consisting essentially of an acrylate polymer which compatibilizes the lipophilic component, i.e. the enhancer, with the hydrophilic polymer base and which renders a uniform composition which is thermodynamically stable. The hydrophilic polymer base affects the mechanical strength, elasticity and adhesive properties and can be one or more hydrophilic polymers selected from the group consisting of polyvinyl alcohol, polyvinyl pyrrolidone, maleic anhydride/vinyl ether copolymer, gelatin, alginate, hydroxyethyl methacrylate, carrageenan, hydroxyethyl cellulose, silicone rubber, agar, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, methyl cellulose, carboxyvinyl copolymer, polyethylene oxide, polyethylene glycol, polyacryl amide, polyhydroxyethyl methacrylate, polydioxolane, polyacrylic acid, polyacryl acetate, polyacryl amide and polyvinyl chloride. The acrylate polymer used as the compatibilizer can be a polymer of alkyl acrylate, alkyl methacrylate, acrylic acid, methacrylic acid or acrylate, or a copolymer thereof. The more preferable acrylate polymer is a copolymer comprising a 1:2 ratio of methyl methacrylate and ethyl acrylate or a copolymer comprising a 1:1 ratio of methacrylic acid and ethyl acrylate. The content of the acrylate polymer used as the compatibilizer in the present invention is within the range of 0.1-10wt.%, and is preferably 2-8wt.% of the entire composition.

The present invention also provides methods of preparing an improved stable hydrogel composition for transdermal drug delivery which contains both a hydrophilic polymer base and lipophilic penetration enhancers. Also provided is a method to compatibilize a hydrophilic polymer base and lipophilic components in order to make a drug delivery preparation that is uniform and stable, thus overcoming the problems exhibited by current

preparations.

Brief Description of the Drawings

FIG. 1 is a schematic diagram of a matrix-type transdermal patch
5 according to the present invention. <Notation of Drawings>

1: Impenetrable base

2: Polymer base including effective drug and permeation enhancer

3: Protection film to be removed before use

FIG. 2 represents the time-course accumulated penetration of
10 buprenorphine hydrochloric acid salt penetrating the skin of a hairless mouse
from a hydrogel matrix containing a lipophilic permeation enhancer and from
a hydrogel matrix not containing a lipophilic permeation enhancer.

FIG. 3 represents the time-course of the weight change of a matrix
caused by leaching of the lipophilic component from a hydrogel matrix that
15 includes an acrylate polymer and a hydrogel matrix that does not include an
acrylate polymer as the compatibilizer.

Detailed Description of the Invention

Before the present composition and method of use thereof for
20 transdermal delivery of pharmaceutical agents are disclosed and described, it
is to be understood that this invention is not limited to the particular
configurations, process steps, and materials disclosed herein as such
configurations, process steps, and materials may vary somewhat. It is also to
be understood that the terminology employed herein is used for the purpose
25 of describing particular embodiments only and is not intended to be limiting
since the scope of the present invention will be limited only by the appended
claims and equivalents thereof.

It must be noted that, as used in this specification and the appended
claims, the singular forms "a," "an," and "the" include plural referents unless
30 the context clearly dictates otherwise. Thus, for example, reference to a
composition for delivering "a drug" includes reference to two or more of such

drugs, reference to "an adhesive" includes reference to one or more of such adhesives, and reference to "a permeation enhancer" includes reference to two or more of such permeation enhancers.

In describing and claiming the present invention, the following 5 terminology will be used in accordance with the definitions set out below.

As used herein, "effective amount" means an amount of a drug or pharmacologically active agent that is nontoxic but sufficient to provide the desired local or systemic effect and performance at a reasonable benefit/risk ratio attending any medical treatment. An effective amount of a permeation 10 enhancer as used herein means an amount selected so as to provide the desired increase in skin permeability and, correspondingly, the desired depth of penetration, rate of administration, and amount of drug delivered.

As used herein, "transdermal" refers to delivery of a drug through the skin or mucosa and thus includes transmucosal delivery. Similarly, "skin" is 15 meant to include mucosa.

As used herein, "drug," "pharmaceutical agent," "pharmacologically active agent," or any other similar term means any chemical or biological material or compound suitable for transdermal administration by the methods previously known in the art and/or by the methods taught in the present 20 invention that induces a desired biological or pharmacological effect, which can include but is not limited to (1) having a prophylactic effect on the organism and preventing an undesired biological effect such as preventing an infection, (2) alleviating a condition caused by a disease, for example, alleviating pain or inflammation caused as a result of disease, and/or (3) either 25 alleviating, reducing, or completely eliminating the disease from the organism. The effect can be local, such as providing for a local anaesthetic effect, or it can be systemic. This invention is not drawn to novel drugs or new classes of active agents. Rather it is limited to the mode of delivery of agents or drugs that exist in the state of the art or that may later be established as active agents 30 and that are suitable for delivery by the present invention. Such substances include broad classes of compounds normally delivered into the body,

including through body surfaces and membranes, including skin. In general, this includes but is not limited to: antiinfectives such as antibiotics and antiviral agents; analgesics and analgesic combinations; anorexics; antihelminthics; antiarthritics; antiasthmatic agents; anticonvulsants; 5 antidepressants; antidiabetic agents; antidiarrheals; antihistamines; antiinflammatory agents; antimigraine preparations; antinauseants; antineoplastics; antiparkinsonism drugs; antipruritics; antipsychotics; antipyretics; antispasmodics; anticholinergics; sympathomimetics; xanthine derivatives; cardiovascular preparations including potassium and calcium 10 channel blockers, beta-blockers, alpha-blockers, and antiarrhythmics; antihypertensives; diuretics and antidiuretics; vasodilators including general coronary, peripheral, and cerebral; central nervous system stimulants; vasoconstrictors; cough and cold preparations, including decongestants; hormones such as estradiol and other steroids, including corticosteroids; 15 hypnotics; immunosuppressives; muscle relaxants; parasympatholytics; psychostimulants; sedatives; and tranquilizers. By the method of the present invention, ionized drugs can be delivered, as can drugs of either high or low molecular weight.

As used herein, "permeation enhancer," "penetration enhancer," 20 "chemical enhancer," or similar terms refer to compounds and mixtures of compounds that enhance the flux of a drug across the skin. The flux can be increased by changing either the resistance (the diffusion coefficient) or the driving force (the gradient for diffusion).

Chemical enhancers are comprised of two primary categories of 25 components, i.e., cell-envelope disordering compounds and solvents, or binary systems containing both cell-envelope disordering compounds and solvents. The latter are well known in the art, e.g. U.S. Patent Nos. 4,863,970 and 4,537,776, incorporated herein by reference.

Cell envelope disordering compounds are known in the art as being useful in 30 topical pharmaceutical preparations. These compounds are thought to assist in skin penetration by disordering the lipid structure of the cell-envelopes of

cells in the stratum corneum. A comprehensive list of these compounds is described in European Patent Application 43,738, published June 13, 1982, which is incorporated herein by reference. Examples of cell envelope disordering compounds that can be used as enhancers, without limitation, 5 include saturated and unsaturated fatty acids and their esters, alcohols, monoglycerides, acetates, diethanolamides, and N,N-dimethylamides such as oleic acid, propyl oleate, isopropyl myristate, glycerol monooleate, glycerol monolaurate, methyl laurate, lauryl alcohol, lauramide diethanolamide, and mixtures thereof. Saturated and unsaturated sorbitan esters, such as sorbitan 10 monooleate and sorbitan monolaurate, can also be used. It is believed that any cell envelope disordering compound is useful for the purposes of this invention.

Suitable solvents include water; diols, such as propylene glycol and glycerol; mono-alcohols, such as ethanol, propanol, and higher alcohols; 15 DMSO; dimethylformamide; N,N-dimethylacetamide; 2-pyrrolidone; N-(2-hydroxyethyl) pyrrolidone, N-methylpyrrolidone, 1-dodecylazacycloheptan-2-one and other n-substituted-alkyl-azacycloalkyl-2-ones (azones) and the like.

20 The present invention is based on the discovery that a stable hydrogel composition can be formulated for transdermal delivery of drugs, wherein an acrylate polymer is used as a compatibilizer which compatibilizes the lipophilic component, i.e. the enhancer, with the hydrophilic polymer base and which renders a uniform composition which is thermodynamically stable.

25 One embodiment of the present invention is characterized by a transdermal hydrogel composition comprising a hydrophilic polymer base, a drug, a lipophilic permeation enhancer and a compatibilizer consisting essentially of an acrylate polymer which compatibilizes the lipophilic component, i.e. the enhancer, with the hydrophilic polymer base and which 30 renders a uniform composition which is thermodynamically stable.

In detail, the transdermal hydrogel composition of the present

invention comprises:

- (1) a hydrophilic polymer base;
- (2) an effective amount of a pharmacologically active drug ;
- (3) a lipophilic permeation enhancer;
- 5 (4) an acrylate polymer elected from the group consisting of alkyl acrylate, alkyl methacrylate, acrylic acid, methacrylic acid or copolymer thereof, which functions as a compatibilizer to enable said lipophilic permeation enhancer to be contained homogeneously and stably in said hydrophilic polymer base; and
- 10 (5) water as a solvent.

The hydrophilic polymer base affects the mechanical strength, elasticity and adhesiveness of the transdermal drug delivery system. Suitable hydrophilic polymers of the present invention can be one or more members selected from the group consisting of polyvinyl alcohol, polyvinyl pyrrolidone, maleic anhydride/vinyl ether copolymer, gelatin, alginate, hydroxyethyl methacrylate, cargeenane, hydroxyethyl cellulose, silicone rubber, agar, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, methyl cellulose, carboxyvinyl copolymer, polyethylene oxide, polyethylene glycol, polyacryl 20 amide, polyhydroxyethyl methacrylate, polydiorganosiloxane, polyacrylic acid, polyacryl acetate, polyacryl amide and polyvinyl chloride. Preferred hydrophilic polymers are selected from the group consisting of polyvinyl alcohol, polyvinyl pyrrolidone, maleic anhydride/vinyl ether copolymer and hydroxyethyl cellulose.

25 The adhesiveness to the skin of the hydrophilic polymer base may be controlled through the selection of said polymers. The adhesive property means viscoelasticity which maintains semipermanent adhesion to most of the bases even under very low pressure. The hydrophilic polymer base in the present invention may have enough adhesiveness property by itself or it may 30 function as a pressure sensitive adhesive, or be combined with additional adhesives, plasticizers or other additives.

It is particularly preferred, in terms of adhesion, to use a mixture of polyvinyl alcohol and polyvinyl pyrrolidone as the hydrophilic polymer base, in the range of 2-30wt.% of polyvinyl alcohol and 2-20wt.% of polyvinyl pyrrolidone based on the weight of the transdermal hydrogel composition, 5 and more preferably in the range of 6-15wt.% of polyvinyl alcohol and 4-15wt.% of polyvinyl pyrrolidone.

When the polyvinyl alcohol content is too low, physical properties like the mechanical strength of the matrix worsen. However, if the polyvinyl alcohol content is too high, it is difficult to contain in the matrix the desired 10 amount of drug, enhancer and other fillers due to an increase of solid particles in the base. Furthermore, the flexibility or adhesiveness of the matrix also worsens. When the polyvinyl pyrrolidone content is too low, the adhesiveness of the matrix worsens and the solubility of drugs in the composition decreases because the polymer functions as auxiliary solvent to 15 the drug. If the polyvinyl pyrrolidone content is too high, the manufacturing process becomes difficult due to an increase in viscosity and decrease in the relative content of fillers like permeation enhancers.

Maleic anhydride/vinyl ether copolymer and/or hydroxyethyl cellulose may be used additionally in the mixture of polyvinyl alcohol and 20 polyvinyl pyrrolidone. Preferably, 0.1-15wt.%, more preferably 3-10wt.%, of hydroxyethyl cellulose and/or 0.1-20wt.%, more preferably 0.2-10wt.%, of maleic anhydride/vinyl ether copolymer, are used additionally. Hydroxyethyl cellulose is known to increase the cohesion of the base and to have an effect of decreasing of skin irritation. However, if the hydroxyethyl cellulose content 25 is high, the manufacturing process becomes difficult due to an increase in viscosity and decrease in the relative content of fillers like permeation enhancers. Maleic anhydride/vinyl ether copolymer even in small amount can improve physical properties like adhesion and mechanical strength of the matrix. However, excessive maleic anhydride/vinyl may increase the 30 viscosity or delay the release of the drug.

The permeation enhancer of the present invention functions by various

mechanisms, such as by increasing the solubility and diffusion of the drug, changing the water-keeping capacity of the keratotic layer, softening the skin, increasing skin permeability, changing the interfacial state of the skin, or functioning as a hair follicle opener. The permeation enhancer of the present invention may work by more than one mechanism but its fundamental function is to increase permeability of the drug through the skin.

For the permeation enhancer, biphasic or lipophilic permeation enhancers, such as hydrophilic permeation enhancers like C₃-C₄ diols or C₂-C₃ alcohols, C₈-C₁₈ saturated or unsaturated fatty acids, C₈-C₁₈ saturated or unsaturated fatty alcohols, C₂-C₄ alkane diols, C₈-C₁₈ fatty acid esters, fatty alcohol ethers, C₈-C₁₈ saturated or unsaturated fatty acids, esters of C₁-C₄ alcohol or terpene compounds, may be used at less than 65wt.% of the total composition.

Examples of permeation enhancers are polyalcohols like propylene glycol, dipropylene glycol and polyethylene glycol, oils like olive oil, squalene and lanolin, fatty alcohol ethers like cetyl ether and oleyl ether, polyethylene glycol ether which increases the solubility of a drug, fatty acid esters like isopropyl myristate or fatty alcohols like oleyl alcohol that increase the diffusion of a drug, urea or urea derivatives like allantoin that affect the water-keeping capacity of the keratin in skin tissue, polar solvents like dimethyl decyl phosphoxide, methyl octyl sulfoxide, dimethyl lauryl amide, dodecyl pyrrolidone, isosorbitol, dimethyl acetonide, dimethyl sulfoxide, decyl methyl sulfoxide and dimethyl formamide that affect the penetration properties of keratin, keratin softeners like salicylic acid, penetration adjuvants like amino acids, hair follicle openers like benzyl nicotinate and high-molecular fatty acid surfactants like lauryl sulfate which change the status of administered drug and skin surface.

In particular, auxiliary solvents may be added to drugs and drug polymers which are hardly soluble in a hydrophilic system. In the present invention, auxiliary solvents like lecithin, retinal derivatives, tocopherol, dipropylene glycol, triacetin, propylene glycol, saturated or unsaturated fatty

acid, mineral oil, silicone fluid and butylbenzyl phthalate may be used.

For another functioning agents, oleic acid, linoleic acid, ascorbic acid, panthenol, butylated hydroxytoluene, tocopherol, tocopheryl acetated, tocopheryl linolate, propyl oleate, isopropyl palmitate, oleamide and 5 polyoxyethylene (4) lauryl ether, polyoxyethylene (2) oleyl ether and polyoxyethylene (10) oleyl ether and polysorbate 20 marketed by ICI America s trade mark Brij™ 30, 93, 97 and Tween™ 20 may be used additionally.


Though the mechanisms of said permeation enhancer, auxiliary solvent and other functioning agents are different, they may be classified as 10 permeation enhancers because they facilitate skin penetration of drugs through the skin. These permeation enhancers can be classified as hydrophilic, lipophilic or biphilic according to their properties. Most of the permeation enhancers, except for hydrophilic skin-penetration facilitators with hydrophilic groups and few carbon atoms like C₃-C₄ diols or C₂-C₃ alcohols, 15 may be classified as lipophilic or biphilic. Specific examples of permeation enhancers are hydrophilic compounds selected from propylene glycol, glycerol, ethanol, isopropyl alcohol, dimethylsulfoxide and n-methyl pyrrolidone; and one or more lipophilic compounds selected from the group consisting of lauryl alcohol, propylene glycol monolaurate, lauroglycol, 20 isopropyl myristate, triacetin, nonanol, oleyl alcohol, linoleyl alcohol, methyl laurate, glycerol monolaurate and glycerol monooleate.

Permeation enhancerd to be used in the present invention includes said known compounds, and its specific examples and more details are described in *Pharm. Tech.*, 1990 Sept., 132-136; *Pharm. Tech.*, 1990 Oct., 54-60; *Pharm. Tech.*, 25 1993 March, 72-98; *Pharm. Tech.*, 1993 Apr., 62-90; and *Pharm. Tech.*, 1993 May, 68-76.

In the polymer hydrogel composition of the present invention, other functioning agents known to facilitate transdermal delivery of drugs may additionally be included.


30 In the present invention, compatibilizers like alkyl acrylate, alkyl methacrylate, acrylic acid, methacrylic acid or acrylate copolymer thereof,

preferably having average molecular weight within the range of 50KD to 5000 KD, more preferably 100KD to 1000 KD, are used to compatibilize the hydrophobic or lipophilic permeation enhancers in the hydrophilic base composition. It is preferable to use an acrylate polymer expressed by the 5 following Formula (1),




wherein R₁ and R₂ may be identical or different and represent a hydrogen atom or C₁-C₈ alkyl; and n represents the number of repeated units (inside the bracket) and is an integer between 500 to 50,000. In said acrylate polymer 15 expressed by Formula (1), R₁ is preferred to be a hydrogen atom or methyl group; and R₂ a methyl or ethyl group.

The more preferable copolymer comprising a 1:2 ratio of methyl methacrylate and ethyl acrylate expressed by the following Formula (1a) or a copolymer comprising a 1:1 ratio of methacrylic acid and ethyl acrylate 20 expressed by the following Formula (1b),



wherein the ratio of n':m' is 1:2, n' is an integer between 200 to 10,000 and m' is an integer between 400 to 20,000.



wherein the ratio of n":m" is 1:1, and "n" and m" is an integer between 300 to 10,000.

5 For the compound expressed by Formula (1a), polymethacrylate compounds marketed as Eudragit™ series by Rohm Pharma (Germany) were used; and for the compound expressed by Formula (1b), polymethacrylate compounds marketed as Kollicoat™ series by BASF (USA) were used, in the Examples of the present invention.

10 The acrylate polymer used as the compatibilizer in the present invention 0.1-10wt.%, preferably 2-8wt.%, of the entire transdermal hydrogel composition. If the compatibilizer content included in the transdermal hydrogel composition is too low, the lipophilic component may be syneresed due to poor compatibility; otherwise if the content is too high, physical 15 properties like the mechanical strength of the matrix may worsen.

The effective drug contained in the transdermal hydrogel composition according to the present invention is pharmacologically or physiologically active for treatment or prevention, and provides a targeted effect when delivered to the body. More specifically, any drug that induces a local or 20 general pharmacological effect for treatment, diagnosis or prevention in plants or animals is regarded to belong to the scope of the present invention. Bioactive drugs like insecticide, pesticides, sunscreens and cosmetics are included in the effective drug list of the present invention. The effective drug is used solely or may be mixed with another effective drug for the prevention, 25 treatment, diagnosis or remedy of diseases or syndromes.

The effective drug is used in a pharmacologically effective amount. This amount means the concentration of a drug that enables a targeted amount of the drug to penetrate the skin with a zero-order penetration rate during the administration period of the drug. This concentration is determined by many 30 parameters including the kind of drug, the administration period of each unit, flow rate of the drug in the system and others. The required amount of

effective drug may be determined empirically from the flow rate of the drug and the permeation enhancer used to penetrate the skin. If the required flow rate is determined, a transdermal administration system is designed to have at least the same release rate with the required flow rate. Of course, the surface area of the transdermal administration system affects the release of the drug from the system. The skin-penetration rate means the rate of drug penetrating the skin. This rate may or may not be affected by the release rate of drug from the carrier, as is known in the field of the related art.

The effective drug and mixtures thereof in the present invention can be provided in various forms for optimal drug delivery. Accordingly, the drug may exist as a free-base, acid, salt, ester, or other pharmacologically available derivative forms or molecular complexes.

Various thickeners, fillers or other additives known to be useful for the transdermal drug delivery system may be added to the transdermal hydrogel composition according to the present invention. For example, addition of materials like clay that absorbs water into the composition, is known to increase the adhesive properties without reducing the drug delivery rate. Examples of the clay are kaolinites like vaolinite, anarchsite, dickite and nacrite, montmorillonites like montmorillonite, bentonite, verdelite and montronite, illites/muscobites like illite and glauconite, chlorites and polygorsites like attapulgite, halloysite, metaboloysite, allophane and aluminum silicate clay.

Also, antiseptics can be included in the composition of the present invention. Examples of antiseptic are sodium azide, aminoethyl sulfonic acid, benzoic acid, sodium benzoate, sodium edetate, cetylpyridinium chloride, benzalkonium chloride, benzetonium chloride, sodium sulfate anhydride, isobutyl *p*-oxybenzoate, isopropyl *p*-oxybenzoate and methyl *p*-oxybenzoate.

The transdermal hydrogel base composition of the present invention can be used as the adhesive part of any transdermal delivery system or in a matrix type apparatus comprising an adhesive monolayer. FIG. 1 is a typical schematic diagram of a matrix type transdermal administration apparatus

comprising an impenetrable base 1, a polymer base 2 including the drug and enhancer, and a protection film 3 to be removed before use. The hydrogel base composition of the present invention can be used as the polymer base 2. Also, the hydrogel base composition of the present invention may be used by 5 adhering it to a common auxiliary base, such as an impenetrable support 1. For the common auxiliary base, a plastic sheet like polyethylene, polypropylene, an ethylene/vinyl acetate copolymer, vynylon, polyester, polyurethane and nylon; a nonwoven fabric like rayon and polyester, a woven fabric like acryl, silk or cotton and a composite layer of these supports may be 10 used.

Hereunder is given a more detailed description of the present invention using examples and comparative examples. However, it should not be construed as limiting the scope of the present invention.

15

Comparative Examples 1 & 2

In Comparative Example 1, a transdermal drug delivery matrix including a hydrophobic permeation enhancer was prepared as follows. In a suitable container, a predetermined amount of buprenorphine hydrochloric acid salt, propylene glycol, triacetin, ethanol, lauryl alcohol, glycerol and pure water were added and stirred until the mixture became completely uniform. A predetermined amount of hydroxyethyl cellulose (number-average molecular weight (M_n): 250,000), and polyvinyl pyrrolidone was then added, dissolved uniformly then followed by addition of a polyvinyl alcohol (degree of polymerization: 500-2,000) aqueous solution and then mixed uniformly, the mixture was then cooled for about 10hr in a 4-10°C refrigerator.

In Comparative Example 2, a matrix not containing a hydrophobic permeation enhancer was prepared the same way as described in Comparative Example 1 except that no triacetin or lauryl alcohol was added. The 30 composition of Comparative Examples 1 & 2 is shown in Table 1.

Table 1

Composition	Content (wt%)	
	Comparative Example 1	Comparative Example 2
Buprenorphine Hydrochloric Acid Salt	2.0	2.0
Propylene Glycol	19.0	24.0
Triacetin (Glycerol Triacetate)	8.5	-
Ethanol	14.0	12.0
Lauryl Alcohol	0.5	-
Glycerol	4.0	4.0
Pure Water	14.0	20.0
Hydroxyethyl Cellulose (M_n : 250,000)	4.0	4.0
Polyvinyl Pyrrolidone (Collidon 90*)	10.0	10.0
25% Polyvinyl Alcohol Solution (degree of polymerization: 500-2,000)	24.0	24.0
Total	100.0	100

The skin-penetration test of the drug for the matrices prepared from Comparative Examples 1 & 2 were performed as follows. The receptor phase 5 of a Franz Cell was filled with pure water and maintained at $32\pm0.5^\circ\text{C}$. The back skin of a male hairless mouse was removed and stabilized for 1hr before the experiment. After cutting the prepared matrix according to the donor cell size, $300\mu\text{L}$ of sample was taken from the cell after 2, 4, 8, 18, 24, 48 and 72hr, and quantitative analysis was performed using liquid chromatography. The 10 results are shown in FIG. 2 and Table 2.

Table 2

Items	Comparative Example 1	Comparative Example 2
Drug Penetration Rate (Flux; $\mu\text{g}/\text{cm}^2/\text{hr}$)	18.49	1.76
Retardation Time (hr)	1.19	0.50

In Comparative Example 1 wherein a lipophilic permeation enhancer was used, the skin-penetration rate was about 10 times higher than that of Comparative Example 2. Though the retardation time of Comparative Example 2 appeared to be short, the retardation time itself was not of great significance because the penetration rate, and hence the penetration amount, was not as great as is shown in FIG. 2. However, the hydrophobic permeation enhancer (triacetin and lauryl alcohol) used in Comparative Example 1 was synergized with time due to the low compatibility between the lipophilic component and the hydrophilic base.

The composition of the present invention overcomes this problem and is illustrated by the following examples.

15 **Example 1**

After adding a predetermined amount of buprenorphine hydrochloric acid salt in a suitable container, a predetermined amount of propylene glycol, triacetin, ethanol, lauryl alcohol, glycerol, BASF's Kollicoat MAE 30D™ as acrylate compatibilizer and pure water were added and stirred until the mixture became completely uniform. After adding a predetermined amount of hydroxyethyl cellulose (M_n : 250,000) and polyvinyl pyrrolidone herein and dissolving them uniformly, a predetermined amount of a polyvinyl alcohol (degree of polymerization: 500-2,000) aqueous solution was added, mixed uniformly, and then cooled for about 10hr in a 4-10°C refrigerator. The composition of Example 1 is shown in the following Table 3.

Table 3

Composition	Content (wt.%)
Buprenorphine Hydrochloric Acid Salt	2.0
Propylene Glycol	19.0
Triacetin (Glycerol Triacetate)	8.5
Ethanol	14.0
Lauryl Alcohol	0.5
Glycerol	4.0
Kollicoat MAE 30D™	8.3
Pure Water	5.7
Hydroxyethyl Cellulose (M_n : 250,000)	4.0
Polyvinyl Pyrrolidone (Collidon 90™)	10.0
25% Polyvinyl Alcohol Solution (degree of polymerization: 500-2,000)	24.0
Total	100.0

In order to identify the increase of compatibility due to the acrylate polymer included in the present invention, the matrices obtained from 5 Example 1 and Comparative Example 1 were sealed with aluminum foil and kept at room temperature. The syneresed liquid portion was removed with Kim Wipes after 0, 1, 2, 4, 8, 16, 24, 48, 72 and 96hr. The weight of the matrices was measured and their change from the initial weight was calculated in %. The results are shown in FIG. 3 and the following Table 4.

Table 4

Time (hr)	Change of Matrix Weight (%), Mean ± S.D.)	
	Comparative Example 1	Example 1
1	96.4± 0.84	99.0± 0.34
2	95.6± .089	99.7± 0.21
4	94.8± 0.21	98.3± 0.74
8	93.2± 0.16	99.3± 0.52
16	92.0± 0.96	99.0± 0.14
24	90.8± 0.91	98.3± 0.38
48	90.4± 0.38	98.0± 0.78
72	90.0± 0.27	97.7± 0.34
96	90.0± 0.41	98.0± 0.24

The weight change of the matrices prepared as in Comparative Example 1 was severe due to syneresation of the thermodynamically unstable composition wherein the lipophilic components were poorly compatible with the hydrophilic polymer base. In addition, volatilization of a volatile solvent like ethanol also contributed to weight loss in some degree. However, in Example 1 wherein an acrylate compatibilizer was used, there was little weight change due to phase separation even after 96hr at room temperature. Therefore, the hydrogel composition of the present invention exhibits superior compatibility and stability of the lipophilic penetration enhancer contained in a hydrophilic polymer base.

Examples 2-14 were performed while adjusting the composition contents of the drug, the hydrogel polymer base and the lipophilic permeation enhancer.

Example 2

Composition	Content (wt.%)
Estradiol	1.0
Propylene Glycol	30.0
Polypropylene Glycol Monolaurate	7.0
Ethanol	14.0
Cremophore RH 40™	0.8
Eudragit NE 30D™	6.7
Pure Water	15.3
Polyvinyl Pyrrolidine (Collidon 30™)	4.0
Maleic anhydride/Vinyl Ether Copolymer (Gantrez AN 169™)	21.2
Total	100.0

Example 3

Composition	Content (wt.%)
Progesterone	1.0
Propylene Glycol	27.0
Lauroglycol (Lacroglyceryl FCC™)	7.0
Ethanol	15.0
Cremophore RH 40™	6.0
Eudragit NE 30D™	6.7
Pure Water	15.3
Polyvinyl Pyrrolidone (Collidon 30™)	4.0
Maleic Anhydride Copolymer (Gantrez AN 169™)	18.0
Total	100.0

Example 4

Composition	Content (wt. %)
Albuterol	2.0
Propylene Glycol	20.0
Isopropyl Myristate	6.0
Isopropyl Alcohol	12.0
Cremophore RH 40™	15.0
Eudragit NE 30D™	11.7
Pure Water	11.8
Polyvinyl Pyrrolidone (Collidon 90™)	4.0
Maleic Anhydride Copolymer (Gantrez AN 169™)	17.5
Total	100.0

Example 5

Composition	Content (wt. %)
Nitroglycerin	3.0
Propylene Glycol	15.0
Triacetin (Glycerol Triacetate)	10.0
Ethanol	14.0
Lauryl Alcohol	3.5
Lactic Acid	2.0
Kollicoat MAE 30D™	18.3
Pure Water	7.2
Polyvinyl Pyrrolidine (Collidon 90™)	4.0
Maleic Anhydride Copolymer (Gantrez AN 169™)	23.0
Total	100.0

Example 6

Composition	Content (wt.%)
Captopril	2.0
Propylene Glycol	12.0
Triacetin (Glycerol Triacetate)	7.0
Ethanol	8.0
Lauryl Alcohol	2.5
Lactic Acid	2.0
Kollicoat MAE 30D™	11.7
Pure Water	12.8
25% Polyvinyl Alcohol Aqueous Solution (Degree of Polymerization: 500-2,000)	32.0
Maleic Anhydride Copolymer (Gantrez AN 169™)	10.0
Total	100.0

Example 7

Composition	Content (wt. %)
Pilocarpine	2.0
Propylene Glycol	19.0
Triacetin (Glycerol Triacetate)	9.0
Ethanol	14.0
Lauryl Alcohol	0.7
Eudragit NE 30D™	11.7
Pure Water	6.6
Hydroxyethyl Cellulose (M_n : 250,000)	4.0
Polyvinyl Pyrrolidone (Collidon 90™)	8.0
20% Polyvinyl Alcohol Aqueous Solution (Degree of Polymerization: 500-2,000)	25.0
Total	100.0

Example 8

Composition	Content (wt.%)
Diazepam	2.0
Propylene Glycol	11.0
Triacetin (Glycerol Triacetate)	5.5
Ethanol	17.5
Lauryl Alcohol	0.6
Nonanol (Nonyl Alcohol)	0.6
Eudragit NE 30D™	9.3
Pure Water	14.0
Hydroxyethyl Cellulose (M_n : 250,000)	4.5
Polyvinyl Pyrrolidone (Collidon 90™)	11.0
25% Polyvinyl Alcohol Aqueous Solution (Degree of Polymerization: 500-2,000)	24.0
Total	100.0

Example 9

Composition	Content (wt.%)
Chlorpromazine	2.0
Propylene Glycol	11.0
Triacetin (Glycerol Triacetate)	4.5
Ethanol	17.5
Propylene Glycol Monolaurate	2.0
Nonanol (Nonyl Alcohol)	0.6
Eudragit NE 30D™	8.0
Pure Water	14.9
Hydroxyethyl Cellulose (M_n : 250,000)	4.5
Polyvinyl Pyrrolidone (Collidon 90™)	11.0
25% Polyvinyl Alcohol Aqueous Solution (Degree of Polymerization: 500-2,000)	24.0
Total	100.0

Example 10

Composition	Content (wt.%)
Lidocaine	2.0
Propylene Glycol	19.5
Triacetin (Glycerol Triacetate)	5.0
Ethanol	14.0
Lauryl Alcohol	0.7
Eudragit NE 30D™	12.7
Pure Water	6.1
Hydroxyethyl Cellulose (M_n : 250,000)	5.0
Polyvinyl Pyrrolidine (Collidon 90™)	11.0
25% Polyvinyl Alcohol Aqueous Solution (Degree of Polymerization: 500-2,000)	20.0
Total	100.0

Example 11

Composition	Content (wt%)
Buprenorphine	2.0
Propylene Glycol	19.5
Triacetin (Glycerol Triacetate)	9.0
Ethanol	14.0
Lauryl Alcohol	0.7
Glycerol	2.0
Eudragit NE 30D™	12.7
Pure Water	12.1
Hydroxyethyl Cellulose (M_n : 250,000)	5.0
Polyvinyl Pyrrolidone (Collidon 90™)	11.0
25% Polyvinyl Alcohol Aqueous Solution (Degree of Polymerization: 500-2,000)	12.0
Maleic Anhydride Copolymer (Gantrez AN 169™)	2.0
Total	100.0

Example 12

Composition	Content (wt. %)
Buprenorphine Hydrochloric Acid Salt	2.0
Propylene Glycol	19.5
Triacetin (Glycerol Triacetate)	9.0
Ethanol	14.0
Lauryl Alcohol	0.7
Glycerol	2.0
Eudragit NE 30D™	12.7
Pure Water	12.1
Hydroxyethyl Cellulose (M_n : 250,000)	5.0
Polyvinyl Pyrrolidone (Collidon 90™)	11.0
25% Polyvinyl Alcohol Aqueous Solution (Degree of Polymerization: 500-2,000)	12.0
Total	100.0

Example 13

Composition	Content (wt%)
Nicotine	14.0
Propylene Glycol	10.0
Triacetin (Glycerol Triacetate)	4.0
Ethanol	15.6
Lauryl Alcohol	1.2
Nonanol (Nonyl Alcohol)	1.2
Eudragit NE 30D™	6.7
Pure Water	15.3
Hydroxyethyl Cellulose (M_n : 250,000)	4.0
Polyvinyl Pyrrolidone (Collidon 90™)	8.0
25% Polyvinyl Alcohol Aqueous Solution (Degree of Polymerization: 500-2,000)	20.0
Total	100.0

Example 14

Composition	Content (wt%)
Prostaglandin-E1	2.0
Propylene Glycol	17.0
Triacetin (Glycerol Triacetate)	8.5
Ethanol	12.0
Lauryl Alcohol	0.5
Glycerol	4.0
Kollicoat MAE 30D™	13.3
Pure Water	4.7
Hydroxyethyl Cellulose (M_n : 250,000)	4.0
Polyvinyl Pyrrolidone (Collidon 90™)	10.0
25% Polyvinyl Alcohol Solution (degree of polymerization: 500-2,000)	24.0
Total	100

As explained above, the transdermal hydrogel composition according
5 to the present invention contains an acrylate polymer as a compatibilizer such
that a hydrophilic polymer base and a lipophilic permeation enhancer can be
applied simultaneously in order to facilitate the effective local or general
skin-penetration of the pharmacologically active drug.

The above description and examples are intended to be illustrative and
10 not limiting of the present invention. One skilled in the art will appreciate
that there may be many variations and alternatives suggested by the above
invention. These variations and alternatives are intended to be within the
scope of this invention as set forth in the following claims.

CLAIMS


What is claimed is:

1. A transdermal drug delivery composition comprising a hydrophilic polymer base, a drug, a lipophilic permeation enhancer and a compatibilizer consisting essentially of an acrylate polymer which compatibilizes said lipophilic enhancer with said hydrophilic polymer base and which renders said composition thermodynamically stable.

- 10 2. The composition according to claim 1, wherein said acrylate polymer is within the range of 0.1-10wt.% based on the entire composition.


- 15 3. The composition according to claim 2, wherein said acrylate polymer is included in the range of 2-8wt.% to the entire composition.

4. The composition according to claim 1, wherein said acrylate polymer is a copolymer comprising a 1:2 ratio of methyl methacrylate and ethyl acrylate expressed by the following Formula (1a),



wherein the ratio of n' to m' is 1:2, n' is an integer between 200 to 10,000 and
25 m' is an integer between 400 to 20,000.

5. The composition according to claim 1, wherein said acrylate polymer is a copolymer comprising a 1:1 ratio of methacrylic acid and ethyl acrylate expressed by the following Formula (1b),



wherein the ratio of n'' to m'' is 1:1 and n'' and m'' is an integer between 300 to 10,000.

6. The composition according to claim 1, wherein said acrylate polymer has
10 average molecular weight in the range of 50KD to 5000KD.

7. The composition according to claim 1, wherein said effective drug is one or
more compounds selected from the group consisting of beta-adrenaline
activators, beta-adrenaline inhibitors, analgesics, antianginas, antiarrhythmic
15 drugs, antidepressants, antiestrogens, antigenadotrophins, hypotensive drugs,
anti-inflammatory drugs, anti-tumor drugs, anti-prostatomegaly drugs,
antipsychotics, spasmolytics, antianxiety drugs, bronchodilators, calcium
regulators, cardiotonics, dopamine receptors, liver enzyme inducers, estrogens,
glucocorticoids, mineral corticoids, monoamine oxidase inhibitors, muscle
20 relaxation drugs, narcotic antagonists, progestogens and peripheral
vasodilators.

8. The composition according to claim 7, wherein said effective drug is one or
more analgesics selected from the group consisting of buprenorphine and
25 fentanyl like fentanyl, norfentanyl, sufentanyl and alfentanyl.

9. The composition according to claim 1, wherein said hydrophilic polymer is
one or more compounds selected from the group consisting of polyvinyl
alcohol, polyvinyl pyrrolidone, maleic anhydride/vinyl ether copolymer,
30 gelatin, alginate, hydroxyethyl methacrylate, cargeenane, hydroxyethyl
cellulose, silicone rubber, agar, hydroxypropyl cellulose, hydroxypropyl

methyl cellulose, methyl cellulose, carboxyvinyl copolymer, polyethylene oxide, polyethylene glycol, polyacrylamide, polyhydroxyethyl methacrylate, polydioxolane, polyacrylic acid, polyacryl acetate, polyacryl amide and polyvinyl chloride.

5

10. The composition according to claim 9, wherein said hydrophilic polymer is one or more compounds selected from the group consisting of polyvinyl alcohol, polyvinyl pyrrolidone, maleic anhydride/vinyl ether copolymer and hydroxyethyl cellulose.

10

11. The composition according to claim 10, comprising 2-30wt.% of polyvinyl alcohol and 2-20wt.% of polyvinyl pyrrolidone based on said hydrophilic polymer.

15

12. The composition according to claim 11, wherein said hydrophilic polymer further comprises 0.1-15wt.% of hydroxyethyl cellulose or 0.1-20wt.% of maleic anhydride/vinyl ether copolymer.

20

13. The composition according to claim 1, wherein said permeation enhancer is one or more compounds selected from the group consisting lauryl alcohol, propylene glycol monolaurate, lauroglycol, isopropyl myristate, triacetin, nonanol, oleyl alcohol, linoleyl alcohol, methyl laurate, glycerol monolaurate and glycerol monooleate.

25

14. The composition according to claim 13, wherein said permeation enhancer is included in the range of 0.1-65wt.% to the entire composition.

30


15. A transdermal drug delivery composition comprising a hydrophilic polymer base comprising 2-30wt.% of polyvinyl alcohol and 2-20wt.% of polyvinyl pyrrolidone of said hydrophilic polymer base; a drug; a 0.1-65wt.% of a lipophilic permeation enhancer based on the entire composition; and

0.1-10wt.% of a compatibilizer based on the entire composition, said compatibilizer consisting essentially of an acrylate polymer which compatibilizes said lipophilic enhancer with said hydrophilic polymer base and which renders said composition thermodynamically stable.

5

16. The composition according to claim 15, wherein said acrylate polymer is included in the range of 2-8wt.% of the entire composition.

17. The composition according to claim 15, wherein said acrylate polymer is a copolymer comprising a 1:2 ratio of methyl methacrylate and ethyl acrylate expressed by the following Formula (1a),




wherein the ratio of n' to m' is 1:2, n' is an integer between 200 to 10,000 and m' is an integer between 400 to 20,000.

20

18. The composition according to claim 15, wherein said acrylate polymer is a copolymer comprising a 1:1 ratio of methacrylic acid and ethyl acrylate expressed by the following Formula (1b),

25



30 wherein the ratio of n'' to m'' is 1:1 and n'' and m'' is an integer between 300 to 10,000.

19. The composition according to claim 15, wherein said acrylate polymer has average molecular weight in the range of 50KD to 5000KD.
- 5 20. The composition according to claim 15, wherein said hydrophilic polymer further comprises 0.1-15wt.% of hydroxyethyl cellulose or 0.1-20wt.% of maleic anhydride/vinyl ether copolymer.
- 10 21. The composition according to claim 15, wherein said permeation enhancer is one or more compounds selected from the group consisting lauryl alcohol, propylene glycol monolaurate, lauroglycol, isopropyl myristate, triacetin, nonanol, oleyl alcohol, linoleyl alcohol, methyl laurate, glycerol monolaurate and glycerol monooleate.
- 15 22. A transdermal drug delivery system comprising the transdermal drug delivery composition according to one of the claims 1 to 21.

DRAWINGS

FIG. 1




FIG. 2





FIG. 3

INTERNATIONAL SEARCH REPORT

International application No.
PCT/KR 01/00783

CLASSIFICATION OF SUBJECT MATTER		
IPC⁷: A61K 9/70, A61F 13/02, A61L 15/16, A61M 37/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
IPC⁷: A61K, A61F, A61L, A61M		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
WPI, EPODOC, PAJ		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 93/00058 A1 (NOVEN PHARMACEUTICALS, INC.) 7 January 1993 (07.01.93) page 17, line 27 - page 18, line 28; page 25, line 22 - page 26, line 8; table II; claims.	1-9,13,14
X	WO 99/15210 A2 (NOVEN PHARMACEUTICALS, INC.) 1 April 1999 (01.04.99) page 8, line 4 - page 10, line 20; page 15, lines 24,30; page 58, line 4 - page 64, line 8, claims 1-3,5,15,16.	1-10,13,14
X	EP 0904778 A1 (NITTO DENKO CORPORATION) 31 March 1999 (31.03.99) abstract, page 4, lines 5-32 and 45; page 5, line 54 - page 6, line 8, claims 1-3.	1,7,9,13
X	WO 95/18603 A1 (NOVEN PHARMACEUTICALS, INC.) 13 July 1995 (13.07.95) page 12, line 16 - page 28, line 37; page 29, line 21 - page 30, line 30; table I; abstract; claims.	
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents: „A“ document defining the general state of the art which is not considered to be of particular relevance „E“ earlier application or patent but published on or after the international filing date „L“ document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) „O“ document referring to an oral disclosure, use, exhibition or other means „P“ document published prior to the international filing date but later than the priority date claimed		
„T“ later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention „X“ document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone „Y“ document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art „&“ document member of the same patent family		
Date of the actual completion of the international search 24 July 2001 (24.07.2001)	Date of mailing of the international search report 16 August 2001 (16.08.2001)	
Name and mailing address of the ISA/AT Austrian Patent Office Kohlmarkt 8-10; A-1014 Vienna Facsimile No. 1/53424/535	Authorized officer KRENN Telephone No. 1/53424/435	

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l application No.

PCT/KR 01/00783

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
EP	A1	904778	31-03-1999	JP A2 11079978		23-03-1999
				US A 6132761		17-10-2000
				JP A2 11079979		23-03-1999
				JP A2 11079980		23-03-1999
WO	A1	9300058	07-01-1993	AU A1 22689/92		25-01-1993
				AU B2 670033		04-07-1996
				BR A 9206208		22-11-1994
				BR A3 1100747		06-06-2000
				CA AA 2110914		07-01-1993
				EP A1 591432		13-04-1994
				EP A4 591432		17-05-1995
				FI A 935833		23-12-1993
				FI A0 935833		23-12-1993
				IL A0 102277		14-01-1993
				IL A1 102277		16-07-2000
				JP T2 6510279		17-11-1994
				MX A1 9203648		31-01-1995
				NO A0 934523		10-12-1993
				NO A 934523		10-02-1994
				NZ A 243200		25-11-1993
				RU C1 2124340		10-01-1999
				SG A1 49164		18-05-1998
				US A 5474783		12-12-1995
				US A 5958446		28-09-1999
				US BA 6235306		22-05-2001
				US A 5656286		12-08-1997
				US A 6024976		15-02-2000
				ZA A 9209992		23-06-1994
				AT E 99176		15-01-1994
				AU A1 32847/89		22-09-1989
				AU B2 606840		14-02-1991
				CA A1 1338660		22-10-1996
				DE CO 68911920		10-02-1994
				DE T2 68911920		07-07-1994
				DK A0 5494/89		03-11-1989
				DK A 5494/89		29-11-1989
				EP A1 418248		27-03-1991
				EP B1 418248		29-12-1993
				FI A0 904358		04-09-1990
				FI B1 1046168		15-03-2000
				HK A1 1006285		19-02-1999
				JP T2 3503283		25-07-1991
				JP B2 2659837		30-09-1997
				KR B1 9513461		08-11-1995
				US A 4814168		21-03-1989
				WO A1 8907950		08-09-1989
				US A 4994278		19-02-1991
				US A 4994267		19-02-1991
				US A 5032207		16-07-1991
				US A 5300291		05-04-1994
				US A 5405406		11-04-1995
				US A 5656285		12-08-1997
				US A 5686099		11-11-1997
				US A 5719197		17-02-1998
				AT E 122240		15-05-1995
				AU A1 50349/90		13-08-1990
				AU B2 632534		07-01-1993
				CA AA 2044132		12-07-1990
				CA C 2044132		06-05-1997
				DE CO 69019175		14-06-1995
				DE T2 69019175		18-01-1996
				DK T3 379045		09-10-1995
				EP A1 379045		25-07-1990
				EP A1 453505		30-10-1991
				EP A1 634179		18-01-1995
				EP B1 379045		10-05-1995
				ES T3 2071683		01-07-1995
				HK A1 1006155		12-02-1999
				IE B 69048		07-08-1996
				JP T2 4502719		21-05-1992
				JP B4 7093939		11-10-1995
				NL A 9020159		02-01-1991
				PT A 92830		31-07-1990
				PT B 92830		29-12-1995
				WO A1 9007940		26-07-1990

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.	
PCT/KR 01/00783	

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
AU	A1	54206/90	21-10-1991
BR	A	9008012	01-12-1992
DK	T3	474647	18-08-1997
EP	B1	474647	05-02-1997
FI	A	924313	25-09-1992
FI	A0	924313	25-09-1992
WO	A1	9114463	03-10-1991
DE	C0	69029909	20-03-1997
DE	T2	69029909	11-09-1997
EP	A1	474647	18-03-1992
NO	A0	923699	24-09-1992
NO	A	923699	01-02-1993
AU	A1	15212/95	01-08-1995
AU	B2	700429	07-01-1999
BR	A	9506470	07-10-1997
CA	AA	2180530	13-07-1995
CN	A	1143318	19-02-1997
EP	A1	737066	16-10-1996
FI	A0	962770	05-07-1996
FI	A	962770	29-08-1996
HU	A0	9601856	30-09-1996
HU	A2	74913	28-03-1997
IL	A0	112269	30-03-1995
IL	A1	112269	22-12-1999
JP	T2	9511987	02-12-1997
NO	A0	962833	05-07-1996
NO	A	962833	15-08-1996
NZ	A	278769	27-04-1998
SG	A1	49331	18-05-1998
WO	A1	9518603	13-07-1995
ZA	A	9500108	25-03-1996
US	BA	6221383	24-04-2001
CA	AA	2025033	16-03-1991
AU	A1	20040/92	21-12-1992
CA	AA	2109099	26-10-1992
EP	A1	592481	20-04-1994
SG	A1	43349	17-10-1997
WO	A1	9219451	12-11-1992
CA	AA	2126366	22-12-1994
IE	A1	940503	28-12-1994
AT	E	144704	15-11-1996
AU	A1	14610/92	06-10-1992
AU	B2	658870	04-05-1995
AU	A1	28331/95	28-09-1995
AU	B2	694243	16-07-1998
CA	AA	2104474	28-08-1992
DE	C0	69214938	05-12-1996
DE	T2	69214938	15-05-1997
DK	T3	573576	01-04-1997
EP	A1	573576	15-12-1993
EP	A2	728477	28-08-1996
EP	A3	728477	11-09-1996
EP	B1	573576	30-10-1996
ES	T3	2094906	01-02-1997
FI	A	933761	26-08-1993
FI	A0	933761	26-08-1993
GR	T3	3022709	31-05-1997
JP	T2	6508820	06-10-1994
NO	A0	933296	16-09-1993
NO	A	933296	01-11-1993
NO	B1	307363	27-03-2000
SG	A1	49158	18-05-1998
WO	A1	9215289	17-09-1992
US	A	5234957	10-08-1993
US	A	5332576	26-07-1994
US	A	5446070	29-08-1995
AU	A1	76722/94	21-03-1995
CA	AA	2170504	02-03-1995
WO	A1	9505813	02-03-1995
WO	A1	9640084	19-12-1996
WO	A1	9606602	07-03-1996
AU	A1	60290/96	30-12-1996
WO	A2	9640086	19-12-1996
WO	A3	9640086	13-02-1997
ZA	A	9604735	19-12-1996

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l application No.	PCT/KR 01/00783
-----------------------	-----------------

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		AT E 148633	15-02-1997
		ES T3 2097145	01-04-1997
		AU A1 34168/95	22-03-1996
		CA AA 2170505	27-02-1996
WO A1 9518603	13-07-1995	AU A1 15212/95	01-08-1995
		AU B2 700429	07-01-1999
		BR A 9506470	07-10-1997
		CA AA 2180530	13-07-1995
		CN A 1143318	19-02-1997
		EP A1 737066	16-10-1996
		FI A0 962770	05-07-1996
		FI A 962770	29-08-1996
		HU A0 9601856	30-09-1996
		HU A2 74913	28-03-1997
		IL A0 112269	30-03-1995
		IL A1 112269	22-12-1999
		JP T2 9511987	02-12-1997
		NO A0 962833	05-07-1996
		NO A 962833	15-08-1996
		NZ A 278769	27-04-1998
		SG A1 49331	18-05-1998
		US A 5656286	12-08-1997
		ZA A 9500108	25-03-1996
		US A 6024976	15-02-2000
		US BA 6221383	24-04-2001
		AT E 99176	15-01-1994
		AU A1 32847/89	22-09-1989
		AU B2 606840	14-02-1991
		CA A1 1338660	22-10-1996
		DE C0 68911920	10-02-1994
		DE T2 68911920	07-07-1994
		DK A0 5494/89	03-11-1989
		DK A 5494/89	29-11-1989
		EP A1 418248	27-03-1991
		EP B1 418248	29-12-1993
		FI A0 904358	04-09-1990
		FI B1 104618	15-03-2000
		HK A1 1006285	19-02-1999
		JP T2 3503283	25-07-1991
		JP B2 2659837	30-09-1997
		KR B1 9513461	08-11-1995
		US A 4814168	21-03-1989
		WO A1 8907950	08-09-1989
		US A 4994278	19-02-1991
		US A 4994267	19-02-1991
		US A 5032207	16-07-1991
		US A 5300291	05-04-1994
		US A 5405486	11-04-1995
		US A 5474783	12-12-1995
		US A 5656285	12-08-1997
		US A 5686099	11-11-1997
		US A 5719197	17-02-1998
		US A 5958446	28-09-1999
		AT E 122240	15-05-1995
		AU A1 50349/90	13-08-1990
		AU B2 632534	07-01-1993
		CA AA 2044132	12-07-1990
		CA C 2044132	06-05-1997
		DE C0 69019175	14-06-1995
		DE T2 69019175	18-01-1996
		DK T3 379045	09-10-1995
		EP A1 379045	25-07-1990
		EP A1 453505	30-10-1991
		EP A1 634179	18-01-1995
		EP B1 379045	10-05-1995
		ES T3 2071683	01-07-1995
		HK A1 1006155	12-02-1999
		IE B 69048	07-08-1996
		JP T2 4502719	21-05-1993
		JP B4 7093939	11-10-1995
		NL A 9020159	02-01-1991
		PT A 92830	31-07-1990
		PT B 92830	29-12-1995
		WO A1 9007940	26-07-1990
		AU A1 22689/92	25-01-1993

INTERNATIONAL SEARCH REPORT

Information on patent family members

In	application No.
PCT/KR 01/00783	

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
AU	B2	670033	04-07-1996
BR	A	9206208	22-11-1994
BR	A3	1100747	06-06-2000
CA	AA	2110914	07-01-1993
EP	A1	591432	13-04-1994
EP	A4	591432	17-05-1995
FI	A	935833	23-12-1993
FI	A0	935833	23-12-1993
IL	A0	102277	14-01-1993
IL	A1	102277	16-07-2000
JP	T2	6510279	17-11-1994
MX	A1	9203648	31-01-1995
NO	A0	934523	10-12-1993
NO	A	934523	10-02-1994
NZ	A	243200	25-11-1993
RU	C1	2124340	10-01-1999
SG	A1	49164	18-05-1998
WO	A1	9300058	07-01-1993
US	BA	6235306	22-05-2001
ZA	A	9209992	23-06-1994
AU	A1	54206/90	21-10-1991
BR	A	9008012	01-12-1992
DK	T3	474647	18-08-1997
EP	B1	474647	05-02-1997
FI	A	924313	25-09-1992
FI	A0	924313	25-09-1992
WO	A1	9114463	03-10-1991
DE	C0	69029909	20-03-1997
DE	T2	69029909	11-09-1997
EP	A1	474647	18-03-1992
NO	A0	923699	24-09-1992
NO	A	923699	01-02-1993
CA	AA	2025033	16-03-1991
AU	A1	20040/92	21-12-1992
CA	AA	2109099	26-10-1992
EP	A1	592481	20-04-1994
SG	A1	43349	17-10-1997
WO	A1	9219451	12-11-1992
CA	AA	2126366	22-12-1994
IE	A1	940503	28-12-1994
AT	E	144704	15-11-1996
AU	A1	14610/92	06-10-1992
AU	B2	658870	04-05-1995
AU	A1	28331/95	28-09-1995
AU	B2	694243	16-07-1998
CA	AA	2104474	28-08-1992
DE	C0	69214938	05-12-1996
DE	T2	69214938	15-05-1997
DK	T3	573576	01-04-1997
EP	A1	573576	15-12-1993
EP	A2	728477	28-08-1996
EP	A3	728477	11-09-1996
EP	B1	573576	30-10-1996
ES	T3	2094906	01-02-1997
FI	A	933761	26-08-1993
FI	A0	933761	26-08-1993
GR	T3	3022708	31-05-1997
JP	T2	6508820	06-10-1994
NO	A0	933296	16-09-1993
NO	A	933296	01-11-1993
NO	B1	307363	27-03-2000
SG	A1	49158	18-05-1998
WO	A1	9215289	17-09-1992
US	A	5234957	10-08-1993
US	A	5332576	26-07-1994
US	A	5446070	29-08-1995
AU	A1	76722/94	21-03-1995
CA	AA	2170504	02-03-1995
WO	A1	9505813	02-03-1995
WO	A1	9640084	19-12-1996
WO	A1	9606602	07-03-1996
AU	A1	60290/96	30-12-1996
WO	A2	9640086	19-12-1996
WO	A3	9640086	19-02-1997
ZA	A	9604735	19-12-1996

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int	application No.
PCT/KR 01/00783	

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
			AT E 148633	15-02-1997
			ES T3 2097145	01-04-1997
			AU A1 34168/95	22-03-1996
			CA AA 2170505	27-02-1996
WO A2	9915210	01-04-1999	AU A1 95813/98	12-04-1999
WO A3	9915210	17-06-1999	EP A2 1021204	26-07-2000
WO B1	9915210	19-08-1999	NO A0 20001567	24-03-2000
			NO A 20001567	25-05-2000